Form 4: GRI Bio Director Granted Future-Dated Stock Options

GRI Bio, Inc. Director David Charles Baker was granted 4,527 stock options with an exercise price of $1.30, effective August 13, 2025.

Summary

• David Charles Baker, a Director of GRI Bio, Inc. (GRI), was granted 4,527 stock options.
• The stock options have an exercise price of $1.30 per share.
• The transaction date and the date the options become exercisable are both August 13, 2025.
• The options expire on August 13, 2035.
• The stock options will vest in four equal quarterly installments, becoming fully vested on the first anniversary of the grant date.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It represents a routine compensation event that aligns director interests with shareholders, without indicating any significant operational or financial changes.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• This represents a form of compensation for the director's service to the company.

Future Outlook

The stock options are structured to vest over one year, in four equal quarterly installments, indicating a forward-looking compensation structure tied to continued service.

Industry Context

The granting of stock options to directors is a common practice across various industries, particularly in biotechnology and emerging growth companies, to attract and retain talent while aligning their interests with long-term shareholder value.

Related Party Transactions

• The grant of stock options to David Charles Baker, a Director of GRI Bio, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon exercise of options, but also benefit from aligned interests with the director.
• Director (David Charles Baker): Receives equity-based compensation, incentivizing performance and long-term commitment to the company.

Next Steps

• The stock options will vest in four equal quarterly installments over the next year, starting from August 13, 2025.

Key Dates

Keywords

GRI Bio, Stock Options, Insider Transaction, Director Compensation, SEC Form 4, Equity Grant, GRI